Reports
Subscribe to
our newsletters!
Showing 1–20 of 84 resultsSorted by latest
-
June of 2025Landscape analysis of Vectorized antibodies by in vivo expression of DNA or RNA regarding stakeholders, R&D pipeline, profile & composition of drug candidates and business deals from an industry perspective...€ 2600.00
-
March of 2025This Competitive Intelligence report about PSMA-Targeted Therapy & Radiodiagnostics provides a competitor evaluation in the field of imaging of PSMA-positive prostate cancer and of PSMA-targeted therapy as of March of 2025€ 500.00
-
March of 20252024 Sales of Therapeutic Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and Therapeutic RNA€ 130.00
-
February of 2025Report with a landscape analysis of PD-(L)1 x VEGF(R) bispecific antibodies regarding stakeholders, R&D pipeline, clinical profile and molecular structure of drug candidates and business deals from an industry perspective...€ 2000.00
-
September of 2024Degrader-Antibody Conjugates 2024: Stakeholders, Technologies, Pipeline and Deals€ 2050.00
-
August of 2024This product provides basic pipeline information on investigational immunotherapeutics targeting CD47 or SIRP-alpha.€ 400.00
-
On the same day of purchaseThis product provides basic pipeline information on investigational antibodies targeting B7-H4.€ 200.00
-
July of 2024This product provides basic information on drugs on the market and drug candidates in R&D as biosimilar antibodies of Actemra/RoActemra (tocilizumab).€ 200.00
-
July of 2024This product provides basic pipeline information on investigational bispecific antibodies targeting PD-L1 and 4-1BB.€ 200.00
-
July of 2024This product provides basic information on drug candidates in research and development as biosimilar antibodies of Keytruda (pembrolizumab)€ 200.00
-
This product provides basic pipeline information on investigational antibodies, antisense and small molecules inhibiting CD38.€ 200.00
-
April of 2024Landscape analysis report and competitor evalulation of claudin 18.2-targeted immunotherapy candidates€ 2150.00
-
April of 2024Competitor evaluation of recombinant antibodies and cellular therapeutics targeting claudin 18.2 as of April 2024€ 430.00
-
March of 2024This product provides basic information on approved and investigational antibodies, cell therapies and small molecules targeting CD38.€ 300.00
-
March of 2024This product provides basic information on inhibitor candidates in research and development targeting TL1A.€ 100.00
-
March of 2024This product provides basic information on immunotherapy candidates in research and development targeting 5T4.€ 100.00
-
March of 20242023 sales data of originator therapeutic proteins and antibodies, selected biosimilars and other biologic drug modalities (gene & cell therapy, RNA)€ 130.00
-
March of 2025Online database of annual global sales of innovator & bioimilar biologics since the year 2007€ 250.00
-
On the same day of purchaseThis product provides basic information on immunotherapeutics in R&D targeting GPC33.€ 300.00
-
On the same day of purchaseThis product provides basic information on immunotherapeutics in R&D targeting Her3.€ 300.00